RT Journal Article
SR Electronic
T1 Highly-Sensitive Lineage Discrimination of SARS-CoV-2 Variants through Allele-Specific Probe Polymerase Chain Reaction
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.01.21265384
DO 10.1101/2021.11.01.21265384
A1 Ratcliff, Jeremy
A1 Al-Beidh, Farah
A1 Bibi, Sagida
A1 Bonsall, David
A1 Costa Clemens, Sue Ann
A1 Estcourt, Lise
A1 Evans, Amy
A1 Fish, Matthew
A1 Folegatti, Pedro M.
A1 Gordon, Anthony C.
A1 Jay, Cecilia
A1 Jennings, Aislinn
A1 Laing, Emma
A1 Lambe, Teresa
A1 MacIntyre-Cockett, George
A1 Menon, David
A1 Mouncey, Paul R.
A1 Nguyen, Dung
A1 Pollard, Andrew J.
A1 Ramasamy, Maheshi N.
A1 Roberts, David J.
A1 Rowan, Kathryn M.
A1 Rynne, Jennifer
A1 Shankar-Hari, Manu
A1 Williams, Sarah
A1 Harvala, Heli
A1 Golubchik, Tanya
A1 Simmonds, Peter
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/11/02/2021.11.01.21265384.abstract
AB Introduction Tools to detect SARS-Coronavirus-2 variants of concern and track the ongoing evolution of the virus are necessary to support public health efforts and the design and evaluation of novel COVID-19 therapeutics and vaccines. Although next-generation sequencing (NGS) has been adopted as the gold standard method for discriminating SARS-CoV-2 lineages, alternative methods may be required when processing samples with low viral loads or low RNA quality.Methods An allele-specific probe polymerase chain reaction (ASP-PCR) targeting lineage-specific single nucleotide polymorphisms (SNPs) was developed and used to screen 1,082 samples from two clinical trials in the United Kingdom and Brazil. Probit regression models were developed to compare ASP-PCR performance against 1,771 NGS results for the same cohorts.Results Individual SNPs were shown to readily identify specific variants of concern. ASP-PCR was shown to discriminate SARS-CoV-2 lineages with a higher likelihood than NGS over a wide range of viral loads. Comparative advantage for ASP-PCR over NGS was most pronounced in samples with Ct values between 26-30 and in samples that showed evidence of degradation. Results for samples screened by ASP-PCR and NGS showed 99% concordant results.Discussion ASP-PCR is well-suited to augment but not replace NGS. The method can differentiate SARS-COV-2 lineages with high accuracy and would be best deployed to screen samples with lower viral loads or that may suffer from degradation. Future work should investigate further destabilization from primer:target base mismatch through altered oligonucleotide chemistry or chemical additives.Competing Interest StatementOxford University has entered into a partnership with AstraZeneca for further development of ChAd-Ox1 nCoV-19. AstraZeneca did not have a role in reviewing the data for this study.Clinical TrialNCT02735707 (REMAP-CAP) NCT04536051 (COV003)Funding StatementThe COV003 trial is supported by the National Institute of Health Research (NIHR), the Lemann Foundation, Rede D'Or, the Brava and Telles Foundation, and AstraZeneca. The REMAP-CAP trial is supported by The Platform for European Preparedness Against (Re-) emerging Epidemics (PREPARE) consortium by the European Union, FP7-HEALTH-2013-INNOVATION-1 (#602525), the Australian National Health and Medical Research Council (#APP1101719), the Australian Medical Research Future Fund (#APP2002132), the New Zealand Health Research Council (#16/631), the Canadian Institutes of Health Research COVID-19 Rapid Research Funding Grant (#447335), the Canadian Institute of Health Research Strategy for Patient-Oriented Research Innovative Clinical Trials Program Grant (#158584), the National Institute for Health Research (UKRIDHSC COVID-19 Rapid Response Rolling Call, "The use of convalescent plasma to treat hospitalised and critically ill patients with COVID-19 disease" (COV19- RECPLAS), the UK National Institute for Health Research (NIHR) and the NIHR Imperial Biomedical Research Centre, the Health Research Board of Ireland (CTN 2014-012), the UPMC Learning While Doing Program, the Translational Breast Cancer Research Consortium, the Pittsburgh Foundation, the French Ministry of Health (PHRC-20-0147), the Minderoo Foundation, and the Wellcome Trust Innovations Project (215522). Australian governments fund Australian Red Cross Lifeblood for the provision of blood products and services to Australia. Collection of UK plasma was funded by the DHSC through core funding under COVID-19 and EU SoHo Grants.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:REMAP-CAP was performed in accordance with regulatory and legal requirements (EudraCT number: 2015-002340-14) and was approved by London-Surrey Borders Research Ethics Committee London Centre (18/LO/0660). COV003 was approved by the Brazilian National Research Ethics Committee (ref: 32604920.5.0000.5505) and the Oxford Tropical Research Ethics Committee (ref: 20-36).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors